Quantum Biopharma (QNTM) Other Non-Current Liabilities (2018 - 2026)

Quantum Biopharma has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $5.3 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $5.3 million, up 87.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (up 87.19% YoY), and the FY2024 annual result was $212002.0, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $5.3 million for Q1 2026 at Quantum Biopharma, down from $7.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.8 million in Q2 2025 to a low of $1.0 in Q2 2024.
• The 5-year median for Other Non-Current Liabilities is $388481.0 (2022), against an average of $1.4 million.
• Across the five-year window, Other Non-Current Liabilities tumbled 100.0% in 2024 and jumped 776068300.0% in 2025, its largest moves.
• Quantum Biopharma's Other Non-Current Liabilities stood at $243594.0 in 2022, then slumped by 46.48% to $130383.0 in 2023, then jumped by 62.6% to $212002.0 in 2024, then jumped by 3560.67% to $7.8 million in 2025, then tumbled by 31.47% to $5.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.3 million (Q1 2026), $7.8 million (Q2 2025), and $2.8 million (Q1 2025), per Business Quant data.